Back to top

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Read MoreHide Full Article

Gilead Sciences (GILD - Free Report) closed at $68.52 in the latest trading session, marking a +1.89% move from the prior day. This move outpaced the S&P 500's daily gain of 1.07%. At the same time, the Dow added 0.65%, and the tech-heavy Nasdaq gained 1.71%.

Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 3.27% over the past month. This has outpaced the Medical sector's loss of 2.4% and the S&P 500's loss of 0.58% in that time.

Investors will be hoping for strength from GILD as it approaches its next earnings release, which is expected to be February 4, 2019. In that report, analysts expect GILD to post earnings of $1.74 per share. This would mark a year-over-year decline of 2.25%. Our most recent consensus estimate is calling for quarterly revenue of $5.52 billion, down 7.24% from the year-ago period.

It is also important to note the recent changes to analyst estimates for GILD. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. GILD is currently a Zacks Rank #3 (Hold).

In terms of valuation, GILD is currently trading at a Forward P/E ratio of 9.79. This valuation marks a discount compared to its industry's average Forward P/E of 24.69.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 58, putting it in the top 23% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Gilead Sciences, Inc. (GILD) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in